Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review-Reference-Cited by-同舟云学术

Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review

Published:2023-04-11 Issue:4 Volume:13 Page:665
ISSN:2218-273X
Container-title:Biomolecules
language:en
Short-container-title:Biomolecules

Author:

Serraino Giuseppe Filiberto¹^ORCID,Jiritano Federica¹^ORCID,Costa Davide²^ORCID,Ielapi Nicola²³^ORCID,Napolitano Desirèe⁴^ORCID,Mastroroberto Pasquale¹^ORCID,Bracale Umberto Marcello⁵^ORCID,Andreucci Michele⁶^ORCID,Serra Raffaele⁷^ORCID

Affiliation:

1. Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy

2. Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy

3. Department of Public Health and Infectious Disease, “Sapienza” University of Rome, 00185 Roma, Italy

4. Ph.D. Student “Digital Medicine” Ph.D. Programm-Magna Graecia, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy

5. Department of Public Health, Vascular Surgery Unit, University of Naples “Federico II”, 80126 Naples, Italy

6. Department of Health Sciences, Nephrology Unit, University of Catanzaro, 88100 Catanzaro, Italy

7. Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic condition determined by an altered collagen turnover of the extracellular matrix. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are abnormally released in patients with HCM. The purpose of this systematic review was to thoroughly summarize and discuss the existing knowledge of MMPs profile in patients with HCM. All studies meeting the inclusion criteria (detailed data regarding MMPs in patients with HCM) were selected, after screening the literature from July 1975 to November 2022. Sixteen trials that enrolled a total of 892 participants were included. MMPs–particularly MMP2—levels were found higher in HCM patients compared to healthy subjects. MMPs were used as biomarkers after surgical and percutaneous treatments. Understanding the molecular processes that control the cardiac ECM’s collagen turnover allows for a non-invasive evaluation of HCM patients through the monitoring of MMPs and TIMPs.

Publisher

MDPI AG

Subject

Molecular Biology,Biochemistry

Link

https://www.mdpi.com/2218-273X/13/4/665/pdf

Reference38 articles.

1. Czimbalmos, C., Csecs, I., Toth, A., Kiss, O., Suhai, F.I., Sydo, N., Dohy, Z., Apor, A., Merkely, B., and Vago, H. (2019). The demanding grey zone: Sport indices by cardiac magnetic resonance imaging differentiate hypertrophic cardiomyopathy from athlete’s heart. PLoS ONE, 14.

2. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J. Am. Coll. Cardiol.,2020

3. Prevalence of pathogenic and likely pathogenic variants in the RASopathy genes in patients who have had panel testing for cardiomyopathy;Aljeaid;Am. J. Med. Genet. Part A,2019

4. Preoperative NT-proBNP Predicts Midterm Outcome After Septal Myectomy;Song;J. Am. Hear. Assoc.,2019

5. Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights;Borer;Thromb. Haemost.,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers in Peripartum Cardiomyopathy—What We Know and What Is Still to Be Found;Biomolecules;2024-01-12

2. Metalloproteinases between History, Health, Disease, and the Complex Dimension of Social Determinants of Health;Journal of Vascular Diseases;2023-07-04